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Abstract
Background: The sieve analysis for the Step trial found evidence that breakthrough HIV-1 sequences for MRKAd5/HIV-1
Gag/Pol/Nef vaccine recipients were more divergent from the vaccine insert than placebo sequences in regions with
predicted epitopes. We linked the viral sequence data with immune response and acute viral load data to explore
mechanisms for and consequences of the observed sieve effect.
Methods: Ninety-one male participants (37 placebo and 54 vaccine recipients) were included; viral sequences were
obtained at the time of HIV-1 diagnosis. T-cell responses were measured 4 weeks post-second vaccination and at the first or
second week post-diagnosis. Acute viral load was obtained at RNA-positive and antibody-negative visits.
Findings: Vaccine recipients had a greater magnitude of post-infection CD8+ T cell response than placebo recipients
(median 1.68% vs 1.18%; p = 0?04) and greater breadth of post-infection response (median 4.5 vs 2; p = 0?06). Viral
sequences for vaccine recipients were marginally more divergent from the insert than placebo sequences in regions of Nef
targeted by pre-infection immune responses (p = 0?04; Pol p = 0?13; Gag p= 0?89). Magnitude and breadth of pre-infection
responses did not correlate with distance of the viral sequence to the insert (p.0?50). Acute log viral load trended lower in
vaccine versus placebo recipients (estimated mean 4?7 vs 5?1) but the difference was not significant (p = 0?27). Neither was
acute viral load associated with distance of the viral sequence to the insert (p.0?30).
Interpretation: Despite evidence of anamnestic responses, the sieve effect was not well explained by available measures of
T-cell immunogenicity. Sequence divergence from the vaccine was not significantly associated with acute viral load. While
point estimates suggested weak vaccine suppression of viral load, the result was not significant and more viral load data
would be needed to detect suppression.
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Introduction
The Step trial evaluated the efficacy of the Merck Adenovirus 5
(MRKAd5) Gag/Pol/Nef vaccine to prevent HIV-1 acquisition
and reduce viral load. Three thousand high-risk HIV-1 negative
individuals at 34 sites in North America, the Caribbean, South
America, and Australia were randomized to vaccine or placebo.
Immunizations were halted in September 2007 based on early
evidence that the vaccine was ineffective at reducing HIV
acquisition or viral load setpoint [1].
Rolland et al. [2] compared breakthrough HIV-1 sequences for
male infected vaccine and placebo recipients to the vaccine insert
sequence. They found greater protein distances to the insert
sequence for vaccine recipients than for placebo recipients when
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restricting the analysis to regions with predicted T-cell epitopes.
Importantly, this sieve effect was specific to the HIV proteins
used in the vaccine, and was not found in other proteins. Thus,
while the vaccine did not protect against infection, it did impact
founding virus populations. Subsequent studies from the RV144
trial have suggested that reduction in acquisition of HIV-1 is
associated with immune responses to envelope, a gene not
included in the MRKAd5 vaccine [3].
This paper explores immunological and virological factors that
may further elucidate the findings of Rolland et al. [2]. Specifically,
we assessed whether pre- or post-infection T-cell responses were
responsible for the viral sequence changes by correlating T-cell
immunogenicity and viral sequence data. In addition, we
evaluated whether the sieve effect on infecting viruses was
associated with acute viral load. Our results indicate that while
anamnestic responses were generated, the vaccine effect on viral
sequences was largely not predicted by available measures of T-
cell function. Neither was sequence divergence from the vaccine
insert found to be significantly associated with viral load. There
was some suggestion that the vaccine had a weak and transient
impact on viral load, although the result was nonsignificant and
future studies with more subjects with acute viral load data would
be needed to confirm the effect.
Methods
Ethics Statement
The protocol was approved by the ethics review committee at
every study site. These committees are: Emory University IRB# 2
and 3; Asociacion Civil Impacta Salud y Educacion IRB #1;
University of Alabama at Birmingham IRB #1 and 2; Brigham
and Women’s Hosp IRB #1 and 2; Massachusetts General
Hospital IRB #1, 2 and 3; New York Blood Center, Inc.; Comite
Institucional de Bioetica de Via Libre; University of Illinois at
Chicago IRB #1; Columbia University Medical Center IRB #1,
2 and 3; Colorado Multiple Institutional Review Board; New York
University School of Medicine IRB; Fenway Community Health
IRB #1; Western IRB; Instituto Dermatologico y Cirugia de Piel
IRB #1; CONABI - Biomedical Public Health; Asociacion Civil
Impacta Salud Y Educacion IRB #1; Jamaica Ministry of Health
IRB #1; University of the West Indies IRB #1; AIDS Research
Alliance Institutional Review Board; Centre hospitalier de
l’Universite de Montreal; North Jersey Community Research
Initiative IRB; University of Pennsylvania IRB #1–5; Children’s
Hospital of Philadelphia IRB #1 and 2; Haitian Group for the
Study of Kaposi’s Sarcoma and Opportunistic Infections (GHES-
KIO) Center IRB #1; Joan and Sanford I Weill Medical College
Cornell University IRB #2; Hospital Universitario Clementino
Fraga Filho IRB #1; University of Rochester IRB #1; San
Francisco General Hospital (SFGH) Committee IRB #2; In-
dependent Review Consulting, Inc. (IRC) IRB #1; St. Vincent’s
Hospital Human Research and Ethics Committee IRB #1; Merck
Institutional Review Board #1; Providence Health Care IRB #1.
All participants provided written informed consent.
Population
The analysis included all 88 male subjects who were HIV
uninfected at entry and diagnosed with HIV infection before
unblinding on October 17, 2007, in addition to three males
diagnosed within two months after unblinding but likely infected
earlier (37 placebo and 54 vaccine recipients in total). Seventy
(78%) were fully vaccinated, 20 (22%) had two vaccinations, and
one (1%) had a single vaccination. One female was infected before
study unblinding and was excluded from additional analysis.
Figure S1 contains a diagram showing the various datasets that are
the subject of this analysis.
Subject Characteristics
The following baseline participant characteristics were included
in certain analyses: race (White vs Non-white); age (# vs .30
years); self-reported circumcision status; HSV-2 serostatus; and
HLA class I type (Protective: expressing HLA-B*57, B*5801 or
B*27 in at least one allele; Unfavorable: expressing B*3502, *3503,
*3504, or *5301 in at least one allele or homozygous in at least one
locus; or Neutral: remaining subjects). Two North American
subjects missing circumcision status were assumed to be circum-
cised, as 78% of other North American subjects in this study were
circumcised. One subject missing HLA type and another missing
HSV-2 serostatus were excluded from analyses involving these
variables.
Pre-infection Immunogenicity Data
Pre-infection T-cell responses were measured by a validated
interferon-gamma (IFNc) ELISpot assay [4] with Mabtech kits
(Stockholm, Sweden) and vaccine-insert-matched peptides (Syn-
pep, Dublin, CA) at 90% purity, using PBMC samples obtained
four weeks post-second vaccination. Samples were stimulated with
pools of peptides 15 amino acids in length and overlapping in
sequence by 11 amino acids at a final concentration of 1 mg/ml
per peptide. Gag, Pol, and Nef pools contained 122, 210, and 51
peptides, respectively. The magnitude of the response was
characterized by the number of spot-forming cells per million
PBMC [5] and positive response criteria were previously published
[4]. Data were available for 46 of the 54 vaccine recipients; eight
were excluded due to HIV-1 infection at the time of analysis.
Responses were mapped to individual 15-mers for 37 of the 46
vaccine recipients as previously described using a final concentra-
tion of 2 mg/ml per peptide [4]. Data were missing for seven due
to insufficient numbers of cells and two due to high background.
The breadth of the response was measured by the number of
reactive 15-mers, with two overlapping 15-mers counted as a single
response.
Viral Sequence Data
Plasma for viral sequencing was obtained from the first available
HIV PCR positive visit (or one month later for one individual) for
67 of the 91 subjects, 27 to 741 days after enrollment
(median= 231 days). Sequence data were missing for 13 subjects
because specimens were not available and for 11 subjects because
HIV-1 could not be amplified by PCR.
Rolland et al. [2] found significant differences between vaccine
and placebo sequences in regions that were predicted to be T-cell
epitopes based on a subject’s HLA alleles. They defined the
‘‘predicted CTL epitope’’ distance between a breakthrough
sequence and the MRKAd5 insert as the HIV-specific evolution-
ary (PAM) distance [6] in peptides predicted to be epitopes in both
sequences, averaged over a subject’s breakthrough sequences. The
‘‘breakthrough K-mers distance’’ is the percentage of predicted
epitopes in the insert sequence that mismatch at least one
breakthrough sequence. Two versions of each distance were
computed using different algorithms for predicting epitopes,
Epipred [7] or NetMHC [8]. Rolland et al. [2] also performed
a ‘‘signature analysis’’ to identify amino acid sites and K-mers at
which the rate of amino acid/peptide mismatch to the insert
differed between breakthrough sequences in vaccine and placebo
groups. Ten signature sites (Gag-84, 211, 403, and 465; Pol-541
and 721; and Nef-64a, 92, 116, and 173) and 14 signature 9-mers
(beginning at Gag-204, Gag-372, two contiguous 9-mers begin-
T-Cell Responses in the Step HIV Vaccine Trial
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ning at Gag-382, six contiguous 9-mers beginning at Gag-398, and
four contiguous 9-mers beginning at Nef-121) were detected and
were assessed in this analysis.
Viral Load Data
Acute viral load was defined as a plasma viral load measured
from an HIV-RNA-positive, ELISA-negative, and Western Blot
borderline or negative sample. The HIV diagnostic and viral load
assays are described in Buchbinder et al. [1]. Twenty-seven
subjects (14 placebo and 13 vaccine recipients) had an acute viral
load measurement available for analysis; for the remaining 64
subjects no samples were collected pre-seroconversion. Of the 19
subjects who had both acute viral load and viral sequence data, 18
had data from the same visit and one had sequence data 28 days
after the acute viral load measurement.
Post-infection Immunogenicity Data
Post-infection T-cell responses were measured at week one
(n = 7) or two (n= 72) post-infection diagnosis by intracellular
cytokine staining (ICS) using pools of PTE-G peptides (Bio-
synthesis, Lewisville, TX [9]) at a final concentration of 1 mg/ml
per peptide as described previously [5,10]. Gag, Pol, and Nef pools
contained 160, 160, and 127 peptides, respectively. Post-infection
responses were available for 79 participants; the remaining 12 had
insufficient cells for testing. The primary measure of immunoge-
nicity was the percent of CD4+ or CD8+ T-cells expressing
interleukin-2 (IL2) and/or IFNc. Positive responses were de-
termined using previously published ICS positivity criteria [10].
Positive peptide pool responses were mapped to individual 15-
mers using IFNc ELISpot as described previously [4]. Breadth was
defined by the number of reactive 15-mers, with two overlapping
15-mers counted as a single response. Data were available for 36
subjects and were missing for one due to low cell viability and 54
due to sample availability. To evaluate preservation of pre-
infection responses, for 23 vaccine recipients, post-infection
responses to individual vaccine-insert-matched 15-mers which
generated pre-infection responses were also assessed using IFNc
ELISpot. Insufficient cells were available for the remaining 23
vaccine recipients with pre-infection T-cell data.
Statistical Methods
The methods are described adjacent to each analysis result for
readability. All p-values are two-sided.
Results
Vaccine-induced Anamnestic Responses
One potential mechanism for the observed sieve effect is
vaccine-induced anamnestic responses. We compared the magni-
tude of the post-infection ICS response between vaccine and
placebo positive responders using a Wilcoxon rank sum test (n = 79
subjects; Figure 1). The magnitude of the CD8+ T-cell response
was found to be greater in vaccine versus placebo recipients
(p = 0?04). The median Gag-Pol-Nef magnitude was 1.68% in
vaccine recipients (SD=1.50%) versus 1.18% in placebo recipi-
ents (SD=1.09%). CD4+T-cell responses did not differ between
treatment groups (p = 0?54; data not shown). Non-insert responses
for CD4+ and CD8+ T-cells were similar between the groups
(p.0?50).
Epitope breadth was also compared between treatment groups
using a Wilcoxon rank sum test (n = 36 subjects; Figure 2). Median
Gag-Pol-Nef breadth was 4.5 vs 2 in vaccine vs placebo recipients.
Breadth of the Gag response was greater in vaccine versus placebo
recipients (p = 0?02) but no difference was detected for Pol or Nef
(p = 0?23 and 0?34, respectively).
HIV infection induced a number of immune responses that
were undetected pre-infection (Figure 3). Based on the 23 vaccine
recipients whose pre-infection responses were tested post-infection,
on average 63?0% of pre-infection responses to Gag-Pol-Nef were
preserved post-infection. Additional analyses of anamnestic
responses are reported in Materials S1 Section 1 (see Table S1;
Figures S2, S3, S4).
Integrated Analysis of Viral Sequences and T-cell
Responses
T-cell response based sieve analysis. Vaccine-induced T-
cell selection pressure would be expected to lead to viral sequence
differences in some fraction of reactive epitopes due to immune
escape. Specifically, within the measured pre-infection reactive
epitopes, we would expect an unusually high rate of mismatches in
vaccine recipient founder sequence epitopes compared to the
corresponding insert epitopes. To address this hypothesis, for each
vaccine recipient we estimated the percentage of mismatches as
the observed rate at which any of his founder sequences
mismatched the insert residue, across all sites within his reactive
15-mers. These percentages were averaged across the vaccine
recipients with at least one positive response, for each protein
region. The 27 placebo subjects with viral sequences were
bootstrapped to generate a null distribution and compute a p-
value.
Among the 32 vaccine recipients with sequence and pre-
infection T-cell response data, 13, 16, and 16 had an ELISpot
response to at least one 15-mer in Gag, Pol, and Nef, respectively.
There were more mismatches than expected by chance in Nef
(p = 0?04), a non-significant trend for Pol (p = 0?13), and no
significant evidence for Gag (p = 0?89). The average percent
mismatch for vaccine recipients, with the median for the null
distribution shown in parentheses, was calculated as 26.1%
(23.3%) for Nef, 6.7% (5.5%) for Pol, and 8.5% (8.3%) for Gag.
Results were similar considering only the most immunodominant
[11] or the most conserved 15-mer for each vaccine recipient (see
Materials S1 Section 2 and Figure S5).
Association between pre-infection T-cell responses and
epitope-based distance measures. If vaccine-induced T-cell
responses led to immune escape, vaccine recipients with greater
pre-infection immune responses would be expected to have viral
epitope sequences with greater distance to the vaccine insert. We
examined associations between the magnitude and breadth of the
pre-infection IFNc ELISpot response (within and across proteins)
and each epitope-based distance measure in the 32 vaccine
recipients with pre-infection T-cell response and sequence data.
Each participant’s majority consensus founder sequence was used;
this is the most common amino acid at each individual site. In
cases of multiple founders, the consensus of the largest founding
population was used. Linear regression was used to compare mean
protein distance by breadth, categorized as: 0 vs. 1–2 vs. .2
reactive 15-mers; and by log10 magnitude of response to the
peptide pools. Seven subjects (22%) had 0 breadth, 6 (19%) had
breadth 1–2, and 19 (59%) had breadth .2. There were no
significant associations between the pre-infection magnitude or
breadth of the vaccine-induced response to a protein and protein
distance in the same or different region (p.0?7 for all pairs of
distance and breadth).
Locations of signature sites in relation to pre-infection T-
cell responses. IFNc ELISpot detected pre-infection responses
to four of the ten signature sites identified by Rolland et al.: [2]
Gag-84, Pol-541, Nef-82, and Nef-173 (Figure 4). Three subjects
T-Cell Responses in the Step HIV Vaccine Trial
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recognized the Gag-84 (T/V) signature. One HLA-A*02 in-
dividual recognized the A02-restricted epitope SLYNTVATL [12]
and two HLA-A*11 individuals recognized the A11-restricted
epitope TLYCVHQK [13]. For the Nef-82 (K/not-K) signature,
two HLA-A*11 individuals recognized the A11-restricted epitope
AVDLSHFLK, just downstream of the signature site (Nef 84–92).
One HLA-A*03 subject recognized the A03-restricted epitope
QVPLRPMTYK, and one subject recognized the 15-mer but the
HLA-restricted epitope was unknown. There were no known
epitopes in the 15-mers covering the Pol-541 or Nef-173 signature
sites.
Acute Viral Load Analysis
We evaluated evidence of a vaccine-induced reduction in acute
viral load by comparing the distribution of log10 acute viral load
between treatment groups using data from all 91 subjects. Sixty-
four missing viral load values were multiply imputed using an
indicator of unfavorable HLA type, study week of HIV diagnosis,
race, age, and circumcision status; and results were combined
across 20 imputed datasets using standard multiple imputation
rules [14]. The estimated mean log acute viral load was lower in
vaccine versus placebo recipients (4?7 vs 5?1; Figure 5) but the
difference was not significant (p = 0?27 Wilcoxon rank sum;
p= 0?21 t-test). Analyses using alternative missing data methods
produced qualitatively similar results (Materials S1 Section 4). A
trend towards reduced acute viral load in the vaccine group was
also seen after stratifying the data by HLA-progression-type
(Figure S6).
Integrated Analysis of Viral Sequences and Acute Viral
Load
We assessed whether there was an association between
breakthrough sequences and acute viral load using the 67 subjects
with viral sequence data. Majority consensus founder sequences
were used and missing viral load values were imputed as described
above. Each epitope-based distance measures was associated with
acute log viral load using a linear model with treatment
assignment, summary distance measure, and an interaction
between treatment and distance as predictors. No associations
were detected in vaccine or placebo groups in any individual
protein or aggregating across Gag, Pol, and Nef (p.0?3 for all
tests), nor was there evidence of a significant difference in
association between treatment groups (p.0?3 for all interaction
tests; Figures S7, S8, S9, S10, S11).
Each individual amino acid site was also examined. A Wilcoxon
rank sum test was used to evaluate differences in acute viral load
between vaccine and placebo recipients with an insert-matched
residue (n = 753 sites assessed). Where nominal p-values were less
than 0?05, q-values measuring the positive false-discovery rate
were calculated [15–17]. We found no individual amino acid sites
Figure 1. Post-Infection Magnitude of CD8+ T-Cell Response. Magnitude of the post-infection CD8+ T-cell response measured by ICS, as
quantified by the percentage of CD8+ T-cells producing IFN or IL-2 when stimulated with the vaccine-insert-matched peptide pools (Gag, Pol, and
Nef) and other non-vaccine-insert peptide pools, for vaccine and placebo groups. Positive responses are indicated using closed red circles and
negative responses using open blue circles. The p-values refer to tests comparing response magnitudes between the vaccine and placebo positive
responders.
doi:10.1371/journal.pone.0043396.g001
T-Cell Responses in the Step HIV Vaccine Trial
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in Gag, Pol, or Nef with treatment differences (p-values ranging
from 0?1 to 1?0). Five sites in Gag were found to be associated with
viral load in the vaccine group alone (Materials S1 Section 5).
Discussion
This study found clear evidence of vaccine-induced anamnestic
responses for CD8+ but not CD4+ T-cells. However the T-cell
response data only partially explained the vaccine-induced
sequence changes identified by Rolland et al. [2]. Pre-infection
T-cell responses did not predict divergence of the breakthrough
sequences from the vaccine insert, yet there was some evidence of
differences between vaccine and placebo breakthrough sequences
in regions with observed pre-infection T-cell responses. This
evidence was concentrated in Nef which has been shown to be
highly immunodominant during acute infection [18].
Analyses of the T-cell data were challenged by methodological
and data availability issues. T-cell responses were sparse such that
few epitopes were recognized by multiple individuals; hence we
had limited power to detect a sieve effect in immunofocused
regions and to correlate the T-cell responses and sequence data.
The T-cell response-based sieve analysis also had limited power
since only a fraction of epitopes may experience selection pressure
due to an immune response. We were limited by sample
availability and minimal overlap between the viral sequence and
immunogenicity data as well. In addition, methodological
improvements, such as refinement of epitope-mapping algorithms
and novel assays, are needed to more directly measure vaccine-
induced T-cell responses. Finally, the immune responses we
measured in the blood do not necessarily reflect responses in the
mucosal tissue which play a key role in early infection.
The vaccine did not significantly reduce acute log viral load,
although the point estimate of a 0.4 log10 reduction suggests the
possibility of weak suppression that would need confirmation in
a study with more acute viral load data. Separate analyses of viral
load data in Step from HIV diagnosis to 4 years post-infection
(median follow-up two years post-infection) demonstrated that the
vaccine did not reduce post-acute viral load [19]. Therefore any
impact of the vaccine on viral load was early and transient.
We tested the following hypotheses regarding the impact of the
viral sequence changes on acute viral load. If vaccine-induced
changes in breakthrough sequences led to decreased viral fitness in
terms of viral load, we would expect higher epitope-based
distances to be associated with lower acute viral load, differentially
Figure 2. Post-Infection Breadth of T-Cell Response. Breath of the post-infection T-cell response as measured by IFNc ELISpot, as quantified by
the number of reactive 15-mers, for the vaccine (grey) and placebo (black) groups. The distribution of breadth is shown for all proteins in aggregate;
for Gag, Pol, and Nef combined; for other non-insert proteins; and for Gag, Pol, and Nef individually. The p-values refer to tests comparing breadth
between vaccine and placebo groups.
doi:10.1371/journal.pone.0043396.g002
T-Cell Responses in the Step HIV Vaccine Trial
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Figure 3. Comparison of Pre- and Post-Infection T-Cell Responses. Pre- and post-infection T-cell responses to individual 15-mers in Gag, Pol,
and Nef as measured by IFNc ELISpot. Each row represents a different subject. Pre-infection responses were measured using vaccine-matched
peptides and post-infection responses were measured using PTE-G peptides.
doi:10.1371/journal.pone.0043396.g003
Figure 4. Signature Sites in Relation to T-Cell Responses. Locations of the signature sites and pre- and post-infection T-cell responses for Gag,
Nef, and Pol. For each protein, the top graph represents the location of post-infection IFNc ELISpot responses detected in 19 vaccine and 11 placebo
recipients (light and medium blue columns, respectively), signature K-mers (red horizontal bars), amino acid signature sites (dashed vertical lines), and
sites where an insert-mismatch was found to be associated with viral load in the vaccine group alone (dotted vertical lines; Materials S1 Section 5).
The bottom graph corresponds to pre-infection IFNc ELISpot responses detected in 27 vaccine recipients (green columns). The region covered by
each responsive peptide is indicated by the box width, and the number of subjects reacting to that peptide is indicated by the box height.
doi:10.1371/journal.pone.0043396.g004
T-Cell Responses in the Step HIV Vaccine Trial
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so in the vaccine group. There are a few examples in the literature
of CTL escape being associated with reduced viral fitness [20–22],
although the SLYNTVATL epitope that encompasses the Gag-84
signature site is well known to escape without fitness cost to the
virus. Alternatively, if vaccine-induced T-cells recognized certain
epitopes and were therefore able to suppress viral replication, we
would expect lower epitope-based distances to be associated with
lower acute viral load among vaccine recipients, but no association
in placebo recipients. Our analyses linking acute viral load with
viral sequence data were designed to be sensitive to either
hypothesis. We found no detectable evidence of a fitness cost as
measured by acute viral load, or of reduced viral replication due to
vaccine-induced epitope recognition.
The viral load analyses were also limited by low power. Acute
viral load was missing for 70% of subjects, largely due to the Step
study’s six-monthly HIV testing from Week 30 on (four weeks after
the last vaccination). This highlights the importance of more
frequent HIV testing in efficacy trials. Had HIV testing been more
frequent, we would likely have been adequately powered to detect
a vaccine effect on acute viral load of the size estimated here,
a reduction of 0?4 log.
Sieve analysis plays a key role in the assessment of immune
correlates. Specifically, it can be useful for identifying the specific
immune responses responsible for any observed vaccine efficacy.
This study emphasizes the need for immune correlates assessments
to be based on assays that are epitope-specific and that are
rigorously validated and have high reproducibility.
Despite detecting vaccine-induced anamnestic responses, this
study found that the observed T-cell responses did not adequately
explain the vaccine effect on founding virus populations identified
by Rolland et al. [2]. Importantly, this implies that the measures of
T-cell response that were employed did not adequately explain
some immune functions that were nonetheless able to put pressure
on the virus. Possible explanations include a lack of sensitivity of
our immune assays or use of inappropriate assays. Neither was
there evidence of a consequence of the viral sequence changes in
terms of acute viral load. Nevertheless, the trend toward modest
viral load suppression in vaccine recipients suggests a hypothesis
that vaccines with improved CD8+ T cell responses may be able to
exert stronger pressure with greater fitness cost and improved viral
load suppression.
Supporting Information
Figure S1 Datasets Included in the Analysis and Associated
Scientific Questions.
(EPS)
Figure S2 Post-Infection Depth of T-Cell Response. Depth of
the post-infection response for vaccine (V) and placebo (P)
recipients. Depth at an amino acid site is defined as the number
of simultaneously elicited variant PTE-G peptides that cover the
site (using HXB2 numbering). The distribution of depth is shown
for Gag, Pol, and Nef combined; for Gag, Pol, and Nef
individually, and for all non-insert proteins. The p-values refer
to tests comparing depth between vaccine and placebo groups.
(EPS)
Figure S3 Post-Infection Responses to Peptides Covering
Signature Sites. The distribution of the number of positive 15-
mers covering the signature sites, for vaccine and placebo groups.
(EPS)
Figure S4 Difference in Magnitude of Positive T-Cell Response
Post- vs Pre-Infection. The difference in the log10 magnitude T-
cell response post- minus pre-infection among the 23 vaccine
recipients whose positive responses pre-infection were tested post-
infection. Only positive post-infection responses are shown. The p-
values refer to tests comparing the mean differences to zero.
(EPS)
Figure S5 Results of T-Cell Response Based Sieve Analysis: The
Null Distribution and Observed Average Mismatch Rate.
Histograms show the bootstrap null distribution of the average
mismatch rate and the vertical lines indicate the observed average
mismatch rate. The two-sided p-value is the fraction of the
bootstrap statistics that are more extreme than the observed
statistic. The top row shows these figures for Gag, Pol, and Nef.
The second row restricts to ‘‘immunodominant’’ responses and the
third row to ‘‘conserved’’ responses.
(EPS)
Figure S6 Acute Log10 Viral Load by HLA Group. The
distribution of acute log10 viral load values in vaccine and placebo
recipients by HLA group. HLA groups are defined as protective
(B27, B57, B5801), unfavorable (B*3502, *3503, *3504, B53, or
homozygous in at least one locus), and neutral haplotypes (all
others). Solid lines correspond to observed means and dashed lines
correspond to means estimated using the multiple imputation
approach.
(EPS)
Figure S7 Association Between Acute Log10 Viral Load and
Each Summary Distance Measure (Gag-Pol-Nef Total). The
predicted CTL epitope distance between a breakthrough sequence
and the MRKAd5 insert is the HIV-specific evolutionary (PAM)
distance in peptides predicted to be epitopes in both sequences,
averaged over a subject’s breakthrough sequences. The break-
through K-mers distance is the percentage of predicted epitopes in
the insert sequence that mismatch at least one breakthrough
sequence. Epitopes were predicted using NetMHC and Epipred.
Missing viral load values were multiply imputed and represent
averages across 20 datasets; solid points are observed values and
open points are averages across 20 imputations. The Pearson
correlation (r) is shown for vaccine (red circles; dashed line) and
placebo (green squares; solid line) groups. Fitted lines from linear
regression models are overlaid.
Figure 5. Acute Log10 Viral Load. The distribution of acute log10
viral load values in vaccine and placebo groups. Solid lines correspond
to observed means and dashed lines correspond to means estimated
using the multiple imputation approach.
doi:10.1371/journal.pone.0043396.g005
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(EPS)
Figure S8 Association Between Acute Log10 Viral Load and
Breakthrough K-mers NetMHC Distance. The breakthrough K-
mers distance is the percentage of NetMHC-predicted epitopes in
the insert sequence that mismatch at least one breakthrough
sequence. Missing viral load values were multiply imputed and
represent averages across 20 datasets; solid points are observed
values and open points are averages across 20 imputations. The
Pearson correlation (r) is shown for vaccine (red circles; dashed
line) and placebo (green squares; solid line) groups. Fitted lines
from linear regression models are overlaid.
(EPS)
Figure S9 Association Between Acute Log10 Viral Load and
Breakthrough K-mers Epipred Distance. The breakthrough K-
mers distance is the percentage of Epipred-predicted epitopes in
the insert sequence that mismatch at least one breakthrough
sequence. Missing viral load values were multiply imputed and
represent averages across 20 datasets; solid points are observed
values and open points are averages across 20 imputations. The
Pearson correlation (r) is shown for vaccine (red circles; dashed
line) and placebo (green squares; solid line) groups. Fitted lines
from linear regression models are overlaid.
(EPS)
Figure S10 Association Between Acute Log10 Viral Load and
Predicted CTL Epitope NetMHC Distance. The predicted CTL
epitope distance between a breakthrough sequence and the
MRKAd5 insert is the HIV-specific evolutionary (PAM) distance
in peptides predicted to be epitopes in both sequences (based on
NetMHC), averaged over a subject’s breakthrough sequences.
Missing viral load values were multiply imputed and represent
averages across 20 datasets; solid points are observed values and
open points are averages across 20 imputations. The Pearson
correlation (r) is shown for vaccine (red circles; dashed line) and
placebo (green squares; solid line) groups. Fitted lines from linear
regression models are overlaid.
(EPS)
Figure S11 Association Between Acute Log10 Viral Load and
Predicted CTL Epitope Epipred Distance. The predicted CTL
epitope distance between a breakthrough sequence and the
MRKAd5 insert is the HIV-specific evolutionary (PAM) distance
in peptides predicted to be epitopes in both sequences (based on
Epipred), averaged over a subject’s breakthrough sequences.
Missing viral load values were multiply imputed and represent
averages across 20 datasets; solid points are observed values and
open points are averages across 20 imputations. The Pearson
correlation (r) is shown for vaccine (red circles; dashed line) and
placebo (green squares; solid line) groups. Fitted lines from linear
regression models are overlaid.
(EPS)
Table S1 List of the 32 peptides covering the signature sites that
were assessed using IFNc ELISpot.
(DOCX)
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